Diabetic Neuropathy - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 75 pages report, published by Global Markets Direct

Keywords : Diabetic Neuropathy Therapeutic Products under Development, Key Players in Diabetic Neuropathy Therapeutics, Diabetic Neuropathy Pipeline Overview, Diabetic Neuropathy Pipeline, Diabetic Neuropathy Pipeline Assessment

Report ThumbnailSeptember-2013
Diabetic Neuropathy - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Diabetic Neuropathy - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Neuropathy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Neuropathy. Diabetic Neuropathy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Diabetic Neuropathy.
- A review of the Diabetic Neuropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Diabetic Neuropathy pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Diabetic Neuropathy.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Diabetic Neuropathy pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Diabetic Neuropathy, H2 2013 9
  • Products under Development for Diabetic Neuropathy - Comparative Analysis, H2 2013 10
  • Products under Development by Companies, H2 2013 11
  • Late Stage Products, H2 2013 13
  • Mid Clinical Stage Products, H2 2013 14
  • Discovery and Pre-Clinical Stage Products, H2 2013 15
  • Assessment by Monotherapy Products, H2 2013 30
  • Assessment by Route of Administration, H2 2013 31
  • Assessment by Stage and Route of Administration, H2 2013 32
  • Assessment by Molecule Type, H2 2013 33
  • Assessment by Stage and Molecule Type, H2 2013 34
  • List of Tables
  • Number of Products Under Development for Diabetic Neuropathy, H2 2013 9
  • Products under Development for Diabetic Neuropathy - Comparative Analysis, H2 2013 10
  • Number of Products under Development by Companies, H2 2013 12
  • Comparative Analysis by Late Stage Development, H2 2013 13
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 14
  • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 15
  • Products under Development by Companies, H2 2013 16
  • Merck & Co., Inc., H2 2013 17
  • Dainippon Sumitomo Pharma Co., Ltd., H2 2013 18
  • Takeda Pharmaceutical Company Limited, H2 2013 19
  • Dong-A Pharmaceutical Co., Ltd., H2 2013 20
  • Neuralstem, Inc., H2 2013 21
  • Lpath, Inc., H2 2013 22
  • DiaMedica Inc., H2 2013 23
  • R-Tech Ueno, Ltd., H2 2013 24
  • Neurotune AG, H2 2013 25
  • Intellect Neurosciences, Inc., H2 2013 26
  • Glucox Biotech, H2 2013 27
  • Vascular Pharmaceuticals, Inc., H2 2013 28
  • TheraQuest Biosciences, LLC, H2 2013 29
  • Assessment by Monotherapy Products, H2 2013 30
  • Assessment by Stage and Route of Administration, H2 2013 32
  • Assessment by Stage and Molecule Type, H2 2013 34
  • Diabetic Neuropathy Therapeutics - Drug Profile Updates 58
  • Diabetic Neuropathy Therapeutics - Discontinued Products 67
  • Diabetic Neuropathy Therapeutics - Dormant Products 68
  • Table of Contents
  • Table of Contents 2
  • List of Tables 5
  • List of Figures 6
  • Introduction 7
  • Global Markets Direct Report Coverage 7
  • Diabetic Neuropathy Overview 8
  • Therapeutics Development 9
  • An Overview of Pipeline Products for Diabetic Neuropathy 9
  • Diabetic Neuropathy Therapeutics under Development by Companies 11
  • Late Stage Products 13
  • Comparative Analysis 13
  • Mid Clinical Stage Products 14
  • Comparative Analysis 14
  • Discovery and Pre-Clinical Stage Products 15
  • Comparative Analysis 15
  • Diabetic Neuropathy Therapeutics - Products under Development by Companies 16
  • Companies Involved in Diabetic Neuropathy Therapeutics Development 17
  • Merck & Co., Inc. 17
  • Dainippon Sumitomo Pharma Co., Ltd. 18
  • Takeda Pharmaceutical Company Limited 19
  • Dong-A Pharmaceutical Co., Ltd. 20
  • Neuralstem, Inc. 21
  • Lpath, Inc. 22
  • DiaMedica Inc. 23
  • R-Tech Ueno, Ltd. 24
  • Neurotune AG 25
  • Intellect Neurosciences, Inc. 26
  • Glucox Biotech 27
  • Vascular Pharmaceuticals, Inc. 28
  • TheraQuest Biosciences, LLC 29
  • Diabetic Neuropathy - Therapeutics Assessment 30
  • Assessment by Monotherapy Products 30
  • Assessment by Route of Administration 31
  • Assessment by Molecule Type 33
  • Drug Profiles 35
  • ranirestat - Drug Profile 35
  • Product Description 35
  • Mechanism of Action 35
  • R&D Progress 35
  • TAK-428 - Drug Profile 37
  • Product Description 37
  • Mechanism of Action 37
  • R&D Progress 37
  • Lpathomab - Drug Profile 38
  • Product Description 38
  • Mechanism of Action 38
  • R&D Progress 38
  • NT-13317 - Drug Profile 39
  • Product Description 39
  • Mechanism of Action 39
  • R&D Progress 39
  • RTU-1096 - Drug Profile 40
  • Product Description 40
  • Mechanism of Action 40
  • R&D Progress 40
  • INN-01 - Drug Profile 41
  • Product Description 41
  • Mechanism of Action 41
  • R&D Progress 41
  • DA-3030 - Drug Profile 42
  • Product Description 42
  • Mechanism of Action 42
  • R&D Progress 42
  • filorexant - Drug Profile 43
  • Product Description 43
  • Mechanism of Action 43
  • R&D Progress 43
  • GLY-230 - Drug Profile 44
  • Product Description 44
  • Mechanism of Action 44
  • R&D Progress 44
  • NSI-566 - Drug Profile 46
  • Product Description 46
  • Mechanism of Action 46
  • R&D Progress 46
  • mepivacaine hydrochloride - Drug Profile 48
  • Product Description 48
  • Mechanism of Action 48
  • R&D Progress 48
  • NT-24336 - Drug Profile 49
  • Product Description 49
  • Mechanism of Action 49
  • R&D Progress 49
  • DA-9801 - Drug Profile 50
  • Product Description 50
  • Mechanism of Action 50
  • R&D Progress 50
  • ARA-290 - Drug Profile 51
  • Product Description 51
  • Mechanism of Action 51
  • R&D Progress 51
  • Drug For Diabetic Neuropathy - Drug Profile 53
  • Product Description 53
  • Mechanism of Action 53
  • R&D Progress 53
  • Stem Cell Therapy For Diabetic Complications - Drug Profile 54
  • Product Description 54
  • Mechanism of Action 54
  • R&D Progress 54
  • VPI-2690-B - Drug Profile 55
  • Product Description 55
  • Mechanism of Action 55
  • R&D Progress 55
  • Drug For Diabetic Neuropathy And Retinopathy - Drug Profile 56
  • Product Description 56
  • Mechanism of Action 56
  • R&D Progress 56
  • DM-433 - Drug Profile 57
  • Product Description 57
  • Mechanism of Action 57
  • R&D Progress 57
  • Diabetic Neuropathy Therapeutics - Drug Profile Updates 58
  • Diabetic Neuropathy Therapeutics - Discontinued Products 67
  • Diabetic Neuropathy Therapeutics - Dormant Products 68
  • Diabetic Neuropathy - Product Development Milestones 69
  • Featured News & Press Releases 69
  • Mar 28, 2013: NeuroMax Receives Permission To Conduct Phase Ib Clinical Trial Of NM-IA-001 For Treatment Of Diabetic Polyneuropathy 69
  • Jan 30, 2013: NeuroMax Successfully Completes Phase Ia Clinical Trials Of NM-IA-001 In Patients With Diabetic Neuropathy 69
  • Nov 27, 2012: ChemoCentryx Announces Initiation Of Phase I Clinical Trial Of CCX872 70
  • Oct 15, 2012: Genkyotex Announces Presentation Of Data From Phase I Studies Of GKT137831 At Kidney Week 2012 70
  • May 10, 2012: NeuroMax Receives Authorization To Conduct Clinical Trials With NM-IA-001 In Russia 70
  • Mar 20, 2012: Astellas Pharma Europe Withdraws Its Applications For Extension Of Indication For Qutenza 71
  • Nov 07, 2011: NephroGenex Reaches Agreement With FDA On Subpart H Phase III Program For Pyridorin 71
  • Oct 31, 2011: J&JPRD Submits Supplemental New Drug Application To FDA For NUCYNTA ER Tablets For Diabetic Peripheral Neuropathic Pain 72
  • Oct 19, 2011: Concert Pharmaceuticals To Present Data On CTP-499 At American Society of Nephrology Kidney Week Meeting 72
  • Oct 18, 2011: NeuroMax Announces Positive Preclinical Trial Results Of NM-IA-001 In Diabetic Neuropathy 73
  • Appendix 74
  • Methodology 74
  • Coverage 74
  • Secondary Research 74
  • Primary Research 74
  • Expert Panel Validation 74
  • Contact Us 75
  • Disclaimer 75

Please select a license type

Share

Related Products

Global Markets DirectDiabetic Neuropathy - Pipeline Review, H2 2013Product ThumbnailDiabetic Neuropathy - Pipeline Review, H2 2013, Industry ReportProduct #: 113289
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved